Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Southern Illinois University

www.siu.edu

Latest From Southern Illinois University

AUA 2016: Studies Suggest Safety Ahead Of Lipocine's Oral Testosterone PDUFA

While Lipocine Inc. is at the nail-biting stage of development for its oral testosterone Tlando (LPCN 1021) – awaiting a US FDA approval decision – urologists continue to study testosterone therapy to determine whether treatment of hypogonadal men is safe with appropriate monitoring.

Companies Clinical Trials

Drugs for Hearing Loss: A Sound Opportunity

Hearing loss is an arena largely ignored by the biopharmaceutical industry, with most of the innovation coming from med-tech players. That situation is ripe for change as a vanguard of start-ups is attempting to develop novel therapies to treat a variety of hearing disorders, including Ménière's disease and sudden sensorineural hearing loss.
BioPharmaceutical Business Strategies

Recent Financings of Private Companies (02/2008)

Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.
See All
UsernamePublicRestriction

Register